NCT06970275Recruiting
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
A Multicentric, Observational, Post-marketing, Registry Study to Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings. Additionally, it assesses how these imaging insights influence clinical decision-making and long-term patient outcomes. Through this comprehensive analysis in a real-world setting, the study seeks to generate valuable insights that can enhance specimen evaluation processes and ultimately improve patient care.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 850 (estimated)
- First submitted
- 25 Apr 2025
- Start date
- 19 Nov 2025
- Primary completion date
- 15 Jan 2031
- Lead sponsor
- XEOS Medical
- Diseases
- Prostate cancer, Head and neck cancer
- NCT number
- NCT06970275
What you commit to
- Study type: Observational
- Planned participants: 850
- From 19 Nov 2025 to the primary completion date, 15 Jan 2031
- 5 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Under the age of 18 years at the time of resective surgery.
Other
- Women who are pregnant or breastfeeding.
Who the study is looking for
- All patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT.
- Patients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AZORG Coordinator of this site? Confirm its status | Aalst | Belgium | Not yet recruiting |
| AZ Maria Middelares Coordinator of this site? Confirm its status | Ghent | Belgium | Recruiting |
| Universitäts-klinikum Essen Coordinator of this site? Confirm its status | Essen | Germany | Recruiting |
| University Hospitals Coventry and Warwickshire (UHCW) NHS Trust Coordinator of this site? Confirm its status | Coventry | United Kingdom | Recruiting |
| UMCG Coordinator of this site? Confirm its status | Groningen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.